(Q39215917)

10 September 2017

title

Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial (English)

1 reference

10 September 2017

0 references

Massimo Corradi

2

0 references

Alberto A Papi

object named as

Alberto Papi

1

0 references

Leonardo M. Fabbri

object named as

Leonardo M Fabbri

7

0 references

author name string

Catherine Pigeon-Francisco

3

1 reference

10 September 2017

Roberta Baronio

4

1 reference

10 September 2017

Zenon Siergiejko

5

1 reference

10 September 2017

Stefano Petruzzelli

6

1 reference

10 September 2017

Klaus F Rabe

8

1 reference

10 September 2017

publication date

4 March 2013

1 reference

The Lancet. Respiratory medicine

10 September 2017

published in

1 reference

10 September 2017

volume

1

1 reference

10 September 2017

issue

1

1 reference

10 September 2017

page(s)

23-31

1 reference

Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma.

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

FDA LABA warning: is there anything new here?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard thera

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

An international observational prospective study to determine the cost of asthma exacerbations (COAX).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Severe exacerbations predict excess lung function decline in asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Rescue treatment in asthma. More than as-needed bronchodilation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Correspondence in relation to critical appraisal by Chapman et al.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Asthma control and activity limitations: insights from the Real-world Evaluation of Asthma Control and Treatment (REACT) study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

The small airways and distal lung compartment in asthma and COPD: a time for reappraisal.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Inflammation of small airways in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Small airway inflammation in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

The influence of lung deposition on clinical response.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Lung function and asthma control with beclomethasone and formoterol in a single inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Not all asthma inhalers are the same: factors to consider when prescribing an inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970012-2

1 reference

7 January 2021

10.1016/S2213-2600(13)70012-2

Identifiers

DOI

1 reference

10 September 2017

1 reference